Contineum Therapeutics, Inc. (CTNM) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Contineum Therapeutics, Inc. (CTNM)
A forensic read on Contineum Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
15.3
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-27.1%
ROE
$531M
Market cap
Contineum Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 15.2, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-28%Return on invested capital.Return on invested capital is -28% and slipping from 14% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+357.9%/yrShare-count dilution.Diluted share count changed +716% over the last 2 years to FY2025 (+357.9%/yr). The count is GROWING — existing holders are being diluted. That's ~357.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~716%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $28,000 of buybacks + dividends in FY2023, but ~$0 in FY2024. A halt usually means the company is conserving cash; understand why before reading it as neutral.
Key fundamentals
Free Cash Flow$-55.5M
Return on Equity-23.0%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Contineum Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CTNM's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown